These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27512662)

  • 21. Development of a robust cell-based potency assay for a coxsackievirus A21 oncolytic virotherapy.
    Chamcha V; He L; Jenny Xu ; Swartz AR; Green-Trexler E; Gurney K; McNeely T
    Heliyon; 2024 Apr; 10(7):e28414. PubMed ID: 38560158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.
    Hadac EM; Kelly EJ; Russell SJ
    Mol Ther; 2011 Jun; 19(6):1041-7. PubMed ID: 21505425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus.
    Deng JZ; Rustandi RR; Swartz A; Shieh Y; Baker JB; Vlasak J; Wang S; Loughney JW
    Mol Ther Oncolytics; 2022 Mar; 24():139-147. PubMed ID: 35024440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of Coxsackievirus A21 procapsids to immobilized glutathione depends on cell culture conditions during infection.
    Swartz AR; Shieh Y; Gulasarian A; Olson JW; Rustandi RR
    Virology; 2022 Aug; 573():167-175. PubMed ID: 35834888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cluster of coxsackievirus A21 associated acute respiratory illness: the evidence of efficient transmission of CVA21.
    Zou L; Yi L; Song Y; Zhang X; Liang L; Ni H; Ke C; Wu J; Lu J
    Arch Virol; 2017 Apr; 162(4):1057-1059. PubMed ID: 28025712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
    Eissa IR; Bustos-Villalobos I; Ichinose T; Matsumura S; Naoe Y; Miyajima N; Morimoto D; Mukoyama N; Zhiwen W; Tanaka M; Hasegawa H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
    Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.
    Newcombe NG; Johansson ES; Au G; Lindberg AM; Barry RD; Shafren DR
    J Virol; 2004 Feb; 78(3):1431-9. PubMed ID: 14722298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.
    Newcombe NG; Beagley LG; Christiansen D; Loveland BE; Johansson ES; Beagley KW; Barry RD; Shafren DR
    J Virol; 2004 Nov; 78(22):12677-82. PubMed ID: 15507656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
    Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
    Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glutathione affinity chromatography for the scalable purification of an oncolytic virus immunotherapy from microcarrier cell culture.
    Swartz AR; Shieh Y; Gulasarian A; Curtis E; Hofmann CF; Baker JB; Templeton N; Olson JW
    Front Bioeng Biotechnol; 2023; 11():1193454. PubMed ID: 37397964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic virotherapy for multiple myeloma.
    Oliva S; Gambella M; Boccadoro M; Bringhen S
    Expert Opin Biol Ther; 2017 Nov; 17(11):1375-1387. PubMed ID: 28796556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The crystal structure of coxsackievirus A21 and its interaction with ICAM-1.
    Xiao C; Bator-Kelly CM; Rieder E; Chipman PR; Craig A; Kuhn RJ; Wimmer E; Rossmann MG
    Structure; 2005 Jul; 13(7):1019-33. PubMed ID: 16004874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
    Rothermel LD; Zager JS
    Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.
    Auffinger B; Ahmed AU; Lesniak MS
    Front Oncol; 2013; 3():32. PubMed ID: 23443138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Intralesional Therapies in Melanoma.
    Agarwala SS
    Oncology (Williston Park); 2016 May; 30(5):436-41. PubMed ID: 27188674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.
    Shafren DR; Au GG; Nguyen T; Newcombe NG; Haley ES; Beagley L; Johansson ES; Hersey P; Barry RD
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):53-60. PubMed ID: 14734451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic virotherapy for multiple myeloma.
    Stief AE; McCart JA
    Expert Opin Biol Ther; 2008 Apr; 8(4):463-73. PubMed ID: 18352850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune System, Friend or Foe of Oncolytic Virotherapy?
    Filley AC; Dey M
    Front Oncol; 2017; 7():106. PubMed ID: 28589085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status.
    Zhang Y; Liu Z
    Curr Pharm Des; 2019; 25(40):4251-4263. PubMed ID: 31682207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions.
    Kim J; Hall RR; Lesniak MS; Ahmed AU
    Viruses; 2015 Nov; 7(12):6200-17. PubMed ID: 26633462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.